A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.

J Transl Med · 2016 · PMC5081668 · PMID 27784336

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

showed a trendp = 0.055so close (0.05 < p ≤ 0.1)

Calprotectin showed a trend towards improvement after 12 weeks treatment with nilotinib decreasing from 359.9 (IQR 183.3–484.9) to 287.9 (IQR 116.7–457.1) ng/ml (p = 0.055), but stayed stable in the placebo group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.